Cancer Antibodies for cancer research

www.bxcell.com antibodies for cancer research

BP0169 BP0016-2 BP0131 BP0063 CD4+ T cells CD4+ T cells Control Control LOB12.3 DTA-1

CD40 (57 kDa)

CTLA-4 (30 kDa) Relative Cell Number Relative Cell Number

Log Fluorescence Intensity Purified CD40 Purified CTLA-4 Log Fluorescence Intensity

InVivoMab InVivoPlus ANTIGEN REACTIVITY APPLICATION CLONE CATALOG CATALOG 4-1BB (CD137) mouse in vivo activation of 4-1BB LOB12.3 BE0169 BP0169 4-1BB (CD137) mouse in vitro 4-1BB blockade, FC 17B5 BE0296 4-1BB (CD137) mouse in vivo and in vitro 4-1BB stimulation 3H3 BE0239 4-1BBL (CD137L) mouse in vivo 4-1BBL blockade TKS-1 BE0110 BTLA (CD272) mouse in vivo BTLA stimulation, in vivo BTLA blockade 6A6 BE0132 BTLA (CD272) mouse in vivo and in vitro stimulation of BTLA, FC PK18.6 BE0153 BTLA (CD272) mouse in vivo BTLA blockade, in vitro stimulation, FC PJ196 BE0196 BTLA (CD272) mouse FC 8F4 BE0210 CD19 mouse in vivo depletion, in vivo CD19 neutralization, in vitro B cell negative selection, FC 1D3 BE0150 CD19 human Flow cytometry, Functional assays, Immunofluorescence, Chimeric antigen construction 4G7 BE0281 CD20 mouse in vivo B cell depletion, FC, WB AISB12 BE0302 CD20 human/monkey in vivo B cell depletion in humanized mice, IHC-F, IP, FC 2H7 BE0276 CD28 mouse in vitro T cell stimulation, in vivo CD28 blockade 37.51 BE0015-1 CD28 mouse in vitro T cell stimulation PV-1 BE0015-5 CD28 rat in vitro T cell stimulation, FC JJ319 BE0040 CD28 human in vitro T cell stimulation 9.3 BE0248 CD28 human/monkey in vitro T cell stimulation/activation, FC, IHC-F CD28.2 BE0291 CD40 mouse in vivo CD40 activation, in vitro B cell stimulation, in vitro DC stimulation FGK4.5/FGK45 BE0016-2 BP0016-2 CD40L (CD154) mouse in vivo and in vitro blocking of CD40/CD40L signaling MR-1 BE0017-1 BP0017-1 CD40L (CD154) human/monkey in vivo and in vitro blocking of CD40/CD40L signaling, IP, FC 5C8 BE0292 CD44 mouse/human in vivo CD44 neutralization IM7 BE0039 CD44 human in vitro CD44 blockade, WB, IF Hermes-1 BE0262 CD47 human in vitro CD47 neutralization, in vivo CD47 neutralization in humanized mice, FC B6H12 BE0019-1 CD47 (IAP) mouse in vivo CD47 blockade, IF MIAP301 BE0270 CD47 (IAP) mouse/human/rat in vivo and in vitro CD47 blockade, IF MIAP410 BE0283 CD70 mouse in vivo and in vitro CD70 blockade, FC FR70 BE0022 CD71 human IHC-F. FC OKT-9 BE0023 CD71 (TfR1) mouse in vivo depletion of CD71+ cells R17 217.1.3/TIB-219 BE0175 CD73 mouse in vivo CD73 blockade TY/23 BE0209 CD80 (B7-1) mouse in vivo CD80 blockade, FC 16-10A1 BE0024 CD80 (B7-1) mouse in vivo CD80 blockade, Affinity chromatography 1G10 BE0134 CD86 (B7-2) mouse in vivo CD86 blockade, FC GL-1 BE0025 CD103 mouse in vivo CD103 neutralization, IF, FC M290 BE0026 CD209b (SIGN-R1) mouse in vivo SIGN-R1 blockade, IHC-F, WB, FC 22D1 BE0220 CD276 (B7-H3) mouse in vivo B7-H3 blockade, FC MJ18 BE0124 c-Kit (CD117) mouse Flow cytometry, Immunofluorescence, Immunohistochemistry 2B8 BE0280 c-Kit (CD117) mouse in vivo mast cell depletion, in vivo c-Kit+ cell depletion, in vitro c-Kit neutralization, IP, FC ACK2 BE0293 c-myc human WB, ELISA, FC 9E10 BE0238 CSF1R (CD115) mouse in vivo macrophage depletion, in vitro CSF-R1 neutralization, in vivo monocyte depletion, FC AFS98 BE0213 BP0213 CTLA-4 (CD152) mouse in vivo and in vitro CTLA-4 neutralization, FC UC10-4F10-11 BE0032 BP0032 CTLA4 (CD152) mouse in vivo and in vitro CTLA-4 neutralization 9H10 BE0131 BP0131

IF – Immunofluorescence | IHC-F – Immunohistochemistry (frozen) | IHC-P – Immunohistochemistry (paraffin) | WB – Western blot | IP – Immunoprecipitation | FC – Flow cytometry (requires fluorochrome conjugation) BP0146 BP0101 InVivoMab vs. InVivoPlus InVivoMab InVivoPlus purity level > 95% > 95% aggregates validated at ≤ 5%

PD- (45 kDa) azide and carrier protein free PD-1 (45 kDa) endotoxin concentration < 2EU/mg < 1EU/mg

validated by WB, FC, or ELISA

tested for murine pathogens

available in bulk quantities Purified PD-1 Purified PD-L1

InVivoPlus InVivoMab InVivoPlus ANTIGEN REACTIVITY APPLICATION CLONE CATALOG CATALOG CATALOG CTLA-4 (CD152) mouse in vivo CTLA-4 neutralization 9D9 BE0164 BP0164 CTLA-4 (CD152) human in vitro CTLA-4 neutralization, FC BN13 BE0190 DR5 (CD262) mouse in vivo and in vitro induction TRAIL-mediated MD5-1 BE0161 EGFR human in vitro EGFR blockade, in vivo EGFR blockade in xenografts, Functional assays, WB 225 BE0278 EGFR mouse/human in vitro EGFR blockade, Functional assays, WB, IP, IHC-P, IF, FC 528 BE0279 E- (CD62E) mouse in vivo and in vitro E-selectin blockade, IHC-F 9A9 BE0294 E-selectin (CD62E) human FC CL2 BE0136 Galectin-9 mouse in vivo Galectin-9 blockade RG9-1 BE0218 GITR mouse in vivo GITR stimulation DTA-1 BE0063 BP0063 GM-CSF mouse in vivo and in vitro GM-CSF neutralization, FC MP1-22E9 BE0259 HER2 (neu) human/rat in vivo and in vitro HER2/neu inhibition, IP, IF, FC 7.16.4 BE0277 ICOS mouse in vivo blocking of ICOS/ICOSL signaling, FC 7E.17G9 BE0059 ICOS mouse FC 27A12 BE0226 ICOSL (CD275) mouse in vivo ICOSL neutralization HK5.3 BE0028 IL-7Rα (CD127) mouse in vivo blocking of IL-7Rα signaling, FC A7R34 BE0065 IL-17F mouse in vivo IL-17F neutralization MM17F8F8.1A9 BE0303 Jagged2 mouse in vivo Jagged 2 neutralization HMJ2-1 BE0125 LAG-3 mouse in vivo and in vitro LAG-3 neutralization, FC C9B7W BE0174 BP0174 LPAM-1 (Integrin α4β7) mouse in vivo Integrin α4β7 neutralization, FC DATK32 BE0034 Ly6G mouse in vivo neutrophil depletion, in vivo MDSC depletion, IF, IHC-P, IHC-F, FC 1A8 BE0075-1 BP0075-1 Ly6G/Ly6C (Gr-1) mouse in vivo depletion of Gr-1+ myeloid cells, FC RB6-8C5 BE0075 BP0075 NKG2D mouse in vivo NKG2D blockade HMG2D BE0111 OX40 (CD134) mouse in vivo and in vitro OX40 activation, WB OX-86 BE0031 BP0031 PD-1 (CD279) mouse in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization J43 BE0033-2 BP0033-2 PD-1 (CD279) mouse in vivo blocking of PD-1/PD-L signaling RMP1-14 BE0146 BP0146 PD-1 (CD279) human in vitro PD-1 neutralization, in vivo PD-1 blockade in humanized mice J116 BE0188 PD-1 (CD279) human FC J110 BE0193 PD-1 (CD279) mouse in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, IHC-F, FC 29F.1A12 BE0273 BP0273 PD-L1 (B7-H1) mouse in vivo PD-L1 blockade, IF, IHC-F, FC 10F.9G2 BE0101 BP0101 PD-L1 (B7-H1) human in vitro PD-L1 blockade, Functional assays, IHC-F, FC 29E.2A3 BE0285 PD-L2 (B7-DC) mouse in vivo and in vitro PD-L2 blockade, IHC-F, FC TY25 BE0112 RANKL (CD254) mouse in vivo RANKL blockade IK22/5 BE0191 TIM-1 mouse in vivo TIM-1 activation, in vitro T cell stimulation/activation, Functional assays, ELISA, FC 3B3 BE0289 TIM-1 mouse in vivo TIM-1 neutralization RMT1-10 BE0113 TIM-3 (CD366) mouse in vivo TIM-3 neutralization, in vitro TIM-3 blocking, FC B8.2C12 BE0275 TIM-3 (CD366) mouse in vivo and in vitro TIM-3 neutralization, FC RMT3-23 BE0115 BP0115 TNFα mouse/rat/rabbit in vivo TNFα neutralization, FC TN3-19.12 BE0244 TYRP1/TRP1 (gp75) mouse/human in vivo triggering of FcγRs, IF, FC TA99 BE0151 VEGFR-2 mouse in vivo and in vitro blocking of VEGFR-2 signaling DC101 BE0060 BP0060 v-H-Ras mouse/human/rat IP Y13-238 BE0139 YB-1 human IHC-P, WB 21A3 BE0216 Bulk Antibodies for in vivo Research www.bxcell.com 1-866-787-3444 ǀ bxcell.com ǀ [email protected] © Bio X Cell 2018